Taiho Oncology Competitors and Similar CompaniesClear all

Taiho Oncology's competitors and similar companies include Shanghai Junshi Biosciences, Biocon, Ethypharm and Takeda Oncology.

	Taiho Oncology Taiho Oncology is a pharmaceutical company engaged in the discovery and development of cancer treatments.	Shanghai Junshi Biosciences Shanghai Junshi Biosciences (上海君實生物醫藥科技) is a biopharmaceutical company focused on the treatment of cancer, autoimmune, and metabolic diseases.	Biocon Biocon is a company that develops and manufactures biopharmaceutical products.	Ethypharm Ethypharm is a specialty pharmaceutical company focused on the treatment of pain and addiction.	Takeda Oncology Takeda Oncology is a biopharmaceutical company developing medicines for the treatment of oncology and inflammation diseases.
Founding Date	Founding Date 2002	Founding Date 2012	Founding Date 1978	Founding Date 1977	Founding Date 1993
Type	Type Subsidiary	Type Public	Type Public	Type Private	Type Subsidiary
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Singapore, SG HQ Oakville, CA Chiyoda City, JP Birmingham, GB Menlo Park, US Princeton, US	Locations Shanghai, CN HQ	Locations Bengaluru, IN HQ Bengaluru, IN Nanakramguda, IN Dublin, IE Kuala Lumpur, MY Puchong, MY Delémont, CH see more	Locations Saint-Cloud, FR HQ Montréal, CA Châteauneuf En Thymerais, FR Nyons, FR Saint Cloud, FR see more	Locations Cambridge, US HQ
Employees	Employees 4191% increase	Employees 2,578	Employees 16,5612% increase	Employees 1,0731% increase	Employees 1,6441% decrease
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ¥2.4b (FY, 2025)	Revenue (est.) ₹167.8b (FY, 2026)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods ¥466.5m (FY, 2025)	Cost of goods ₹56.9b (FY, 2026)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit ¥2b (FY, 2025)	Gross profit ₹115.8b (FY, 2026)	Gross profit N/A	Gross profit N/A
Net income	Net income N/A	Net income (¥1b) (FY, 2025)	Net income ₹3.7b (FY, 2026)	Net income N/A	Net income N/A